[{"address1": "1185 Avenue of the Americas", "address2": "3rd Floor", "city": "New York", "state": "NY", "zip": "10036", "country": "United States", "phone": "973 242 0005", "website": "https://www.synaptogen.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Synaptogenix, Inc. operates as a clinical-stage biopharmaceutical company. It is conducting clinical and preclinical studies of its lead therapeutic candidate, Bryostatin-1, in Alzheimer's disease. Its preclinical studies have also demonstrated bryostatin's regenerative mechanisms of action for the rare disease Fragile X syndrome, and for other neurodegenerative disorders, such as multiple sclerosis, stroke, and traumatic brain injury. The U.S. Food and Drug Administration has granted Orphan Drug Designation to Synaptogenix for Bryostatin-1 as a treatment for Fragile X syndrome. The company was incorporated in 2012 and is headquartered in New York, New York.", "fullTimeEmployees": 5, "companyOfficers": [{"maxAge": 1, "name": "Dr. Alan J. Tuchman M.D., MBA(FAAN)", "age": 77, "title": "CEO & Director", "yearBorn": 1947, "fiscalYear": 2023, "totalPay": 303347, "exercisedValue": 0, "unexercisedValue": 50088}, {"maxAge": 1, "name": "Dr. Daniel L. Alkon M.D.", "age": 82, "title": "President, Chief Scientific Officer & Director", "yearBorn": 1942, "fiscalYear": 2023, "totalPay": 375000, "exercisedValue": 0, "unexercisedValue": 109125}, {"maxAge": 1, "name": "Mr. Robert  Weinstein", "age": 64, "title": "CFO, Executive VP, Treasurer & Secretary", "yearBorn": 1960, "fiscalYear": 2023, "totalPay": 568918, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 4, "previousClose": 3.02, "open": 3.02, "dayLow": 3.0101, "dayHigh": 3.1799, "regularMarketPreviousClose": 3.02, "regularMarketOpen": 3.02, "regularMarketDayLow": 3.0101, "regularMarketDayHigh": 3.1799, "beta": 1.293, "trailingPE": 3.420568, "forwardPE": -0.35247073, "volume": 9569, "regularMarketVolume": 9569, "averageVolume": 18937, "averageVolume10days": 8050, "averageDailyVolume10Day": 8050, "marketCap": 4080521, "fiftyTwoWeekLow": 2.32, "fiftyTwoWeekHigh": 7.225, "fiftyDayAverage": 3.17832, "twoHundredDayAverage": 3.592145, "currency": "USD", "enterpriseValue": -17674076, "floatShares": 1346503, "sharesOutstanding": 1355610, "sharesShort": 25369, "sharesShortPriorMonth": 19833, "sharesShortPreviousMonthDate": 1735603200, "dateShortInterest": 1738281600, "sharesPercentSharesOut": 0.0187, "heldPercentInsiders": 0.01949, "heldPercentInstitutions": 0.01082, "shortRatio": 1.13, "shortPercentOfFloat": 0.0188, "impliedSharesOutstanding": 1355610, "bookValue": 9.444, "priceToBook": 0.31873146, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1727654400, "netIncomeToCommon": -9132406, "trailingEps": 0.88, "forwardEps": -8.54, "lastSplitFactor": "1:25", "lastSplitDate": 1712275200, "enterpriseToEbitda": 2.615, "52WeekChange": -0.4285714, "SandP52WeekChange": 0.22903383, "exchange": "NCM", "quoteType": "EQUITY", "symbol": "SNPX", "underlyingSymbol": "SNPX", "shortName": "Synaptogenix, Inc.", "longName": "Synaptogenix, Inc.", "firstTradeDateEpochUtc": 1607437800, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EST", "uuid": "d14ff140-0ac6-3af9-a386-f918dc6aa47f", "messageBoardId": "finmb_268943522", "gmtOffSetMilliseconds": -18000000, "currentPrice": 3.0101, "recommendationKey": "none", "totalCash": 22069080, "totalCashPerShare": 16.28, "ebitda": -6758923, "quickRatio": 64.739, "currentRatio": 65.359, "returnOnAssets": -0.15322, "returnOnEquity": -0.39562, "freeCashflow": -5142445, "operatingCashflow": -4782123, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2025-02-15"}]